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Summary
We have tested the binding of HLA class I proteins to peptides usinga solid-phase binding assay.
We tested 102 peptides, mostly derived from the HIV gag and HIVpol sequences. Most peptides
did not bind to any class I protein tested. The pattern ofbinding among the three class I proteins
tested, HLAA2, -B27, and -B8, was appropriately 85% concordant. Further, all five ofthe known
HIV-1 gag T cell epitopes detected by human CTL bound at least one class I protein. Binding
ofclassI to the peptides couldbe detected either by directly iodinated classI proteins, or indirectly
using monoclonal antibodies specific for class I. The binding to the plates couldbe blocked with
MA2.1, which binds in the al region of A2, but not by W6/32, which binds elsewhere. The
data presented here show that binding of class I to peptides is specific, but that many peptides
bind to more than a single class I protein.
T
he MHC plays an important role in regulation of the
immune response. The roles of both class I and class II
molecules have been extensively investigated (1). It is now
clear that class I molecules play a crucial role in recognition
of virus infected cells by cytotoxic T cells (2). Class II mole-
cules regulate afferent immune responses by their presenta-
tion of peptide fragments, primarily to helper T cells. Both
Grey and colleagues and Unanue and colleagues have directly
shown that fragments of peptides from immunogenic pro-
teinsbind directly to MHC class II molecules (3-6) . Further
they showed the binding patterns of peptides to class II mol-
ecules correlated fairly well with the ability of presenting cells
to functionally display those same peptides to T cells (5).
There is ample indirect evidence that similar peptide frag-
ments of proteins can bind to MHC classI molecules as well.
This binding converts cellsexpressing appropriate class I pro-
teins into targets for antigen-specific CTL (7, 8). Competi-
tion experiments showed that most peptides that were epi-
topes presented by that molecule couldcompete for the ability
to sensitize targets for T cell killing (9, 10), although in some
cases competition was unidirectional (11) .
It has been much more difficult to demonstrate the direct
binding of class I proteins to peptides than the binding of
class II proteins to peptides. Two recent preliminary reports
have appeared, suggesting that binding of class I proteins to
peptides can occur in vitro (12, 13). The results which we
present here expand on those previous results and demon-
strate substantial specificity ofbinding of class I to peptides.
Surprisingly the data here show that a peptide which binds
to a class I molecule is likely to bind to other class I proteins.
Materials and Methods
Peptides.
￿
The HIV-1 (SF-2) gag peptides used in these studies
were supplied by the MRC AIDS directed research program, and
were synthesized by Cambridge Research Biochemicals. The pol
peptides were a gift of R. Young, Whitehead Institute, Cambridge,
MA. Influenza A matrix protein peptide 57-68 with lysine sub-
stituted at position 65 (K65), and influenza nucleoprotein peptide
380-393 were kindly supplied byJ. Rothbard, Immulogic Corp.
All peptides used werejudged >80% pureby HPLC. The sequences
of all the peptides used in these studies are shown in Fig. 1.
Purification of Class I Molecules.
￿
HLA class I molecules were
purified essentially as described by Bouillot (13). In brief, 2 x 10'
lymphoblastoid cell lines (9004 [(HLA-A2; B27) from the ASHI
Serum Bank and Cell Repository] or B cell line JM [A2;B51,62],
and PF 04015 [A1;B8]) were extracted in 100 ml of TSB (10 mM
Tris-HCI, 0.15 M NaCI, pH 7.5) with protease inhibitors and 1%
NP-40 for 60 min. Extracts were centrifuged at 8,000 rpm for 25
min at 4°C. Supernatants were passed at 5 ml/h at 4°C over a
mock protein-coupled CNBr-activated Sepharose column, and next
over a sequence of three columns coupled with irrelevant IgGl;
mAb MA2.1 (HLA-A2 specific); and mAb ME.1 (HLA-B27
specific), respectively (14-16). The Al/BS molecules were eluted
from a W6/32 column. All mAbs were purified from tissue cul-
ture supernatant by affinity chromatography using Sepharose-pro-
tein A columns. The columns coupled with MA2.1 and ME.1 were
washed separately with 100 ml ofTSB, 1% NP-40; TSB, 1% NP-
40, 0.5 M NaCl; and TSB, 0.1% NP-40. HLA-A2 and HLA-1327
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Sequences of peptides used in these studies. Sequences are shown in the one-letter amino acid code.
were eluted with diethylamine (0.05 M, pH 11.5) + 0.1% NP-40.
1-ml fractions were collectedin tubes containing 0.8 ml of 0.1 M
phosphate buffer, pH 6.7. Protein-containing fractions as deter-
mined with the BCA reagent (Pierce Chemical Co., Rockland,
IL) were combined and dialyzed for16 hagainst PBS + 0.1% NP-
40 at 4°C. Purity was assessed by SDS-PAGE and staining with
Coomassie Blue. Purified preparations gave two bands, one at 43
kD and one at 12 kD, as expected for class I heavy chain and (32
(data not shown). Special care was taken with all preparations to
ensure each was free of actin contamination. Isoelectric, focusing
wasalso performed on the samples followingiodination, as previ-
ously described (17). No A2 was detected in theB27 preparations,
andno B27 wasdetectable in theA2 preparations (datanot shown).
Aliquots were stored at -70°C until used.
Iodination ofMHC Class IProteins.
￿
100 Ecl of purified material
was incubated for 60 s at room temperature with 0.5 mCi of I'll
and 10 P,1 of chloramine T (5 mg/ml) . The reaction was termi-
natedby the addition of 30 P.1 of sodium metabisulfite and2.5 ml
PATB buffer (PBS, 1% BSA, 0.05% tween 20, 0.02% sodium
azide). Theiodinatedmaterial wasfreedofunboundiodine by pas-
sage over Sephadex G-25 columns, PMSF (0.1 mM) and trypsin
inhibitor (10 P,g/ml) were added, and it was stored at 4°C. All
preparations were used within 14 d.
Binding Assays,
￿
The direct binding assay of class I to peptide
wascarried out essentially as describedby Bouillot et al. (13). Flat-
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or U-bottomed flexible polyvinylchloride plates (No. 3912, Falcon
Labware, Oxnard, CA) were pretreated for 2 h with 2.5%
glutaraldehyde (inwater). Peptides were dissolved in 50% DMSO
at 1-5 mg/ml, (or in some experiments testing thepol peptides,
10% DMSO in RPMI 1640) anddiluted in PBS to 50-100 Wg/ml.
Thepolpeptides were coated on untreatedplates. 100P,1was added
per well and incubated overnight at 4°C. Next the plates were
blocked with PATB (2 h RT). For direct binding assays, 50 /Al of
"'I A2 or B27 was added per well at 2 x 106 cpm/ml. After over-
nightincubation at 4°C, the plates were washed three times with
PATB buffer, and individual wells were counted.
Alternatively, unlabeled HLA was incubated in peptide coated
plates overnight at 4°C. Binding of unlabeled HLAwas detected
using reactivity with class I-specific mAbs (MA2.1 forA2; ME.1
for B27; or W6/32 for others), either directly iodinated or with
a sandwich assay, using unlabeled antibodies either 'III (Amer-
sham)or alkaline phosphatase (Sigma Chemical Co., St. Louis, MO)
labeled goat anti-mouse antibody. Alkaline phosphatase was de-
tected usingp-nitrophenyl phosphate (Sigma)andreading theplates
directly on a plate reader at 405 and 690 nM.
Forcompetition assays, afterblocking andwashing, 50 P.1 PATB
buffer with different concentrations of competing peptideand 50
,,1 1251-labeled HLA (2-4 x 106 cpm/ml) were mixed, incubated
for 2 h at RT, and added to coated plates. Incubation, washing,
and harvesting were as describedfor thedirect bindingexperiments.
45 . VQLGIPHPAGLKKKKSVTVLDVGDA 74 . ASDFNLPPVVAKEIVASCDKCQLKG
HIV aav Peptides 46 . TVLDVGDAYFSVPLDEDFRKYTAFT 75 . CDKCQLKGEAMHGQVDCSPGIWQLD
-21 ILKALGPAATLEEMMC
P17-1 CMGARASVLSGGELDK 47 . FRKYTAFTIPSTNNETPGIRYQYNV 76 . SPGIWQLDCTHLEGKVILVAVHVAS
-22 LEEMMTACQGVGGPGY
-2 GELDKWEKIRLRPGG 48 . GIRYQYNVLPQGWKGSPAIFQSSMT 77 . LVAVHVASGYIEAEVIPAETGQETA
-23 CVGGPGHKARVL
-3 CLRPGGKKKYKLKHIV 49 . AIFQSSMTKILEPFRKQNPDIVITQ 78 . AETGQETAYFLLKLAGRWPVKTIHT
P15-14 CAEAMSQVTNPANIMM
-4 CLKHIVWASRELERFA 50 . NPDIVITQYMDDLYVGSDLEIGQHR 79 . WPVKTIHTDNGSNFTSATVKAACWW
-15 CANIMMQRGNFRNQRK
-5 CLERFAVNPGLLETSE 51 . DLEIGQHRTKIEELRQHLLRWGLTT 80 . TVKAACWWAGIKQEFGIPYNPQSQG
-16 RNQRKTVKCFNGKE
-6 LETSEGCRQILGQLQ 52 . LLRWGLTTPDKKHQKEPPFLWMGYE 81, PYNPQSQGVVESMNKELKKIIGQVR
-17 NCGKEGHIAKNCPAPN
-7 CLGQLQPSLQTGSEEL 53 . PFLWMGYELHPDKWTVQPIVLPEKD 82 . KKIIGQVRDQAEHLKTAVQMAVFIH
-18 NCRAPRKKGCWRCGR
-8 CGSEELRSLYNTVATL 54 . PIVLPEKDSWTVNIDQKLVGKLNWA 83 . VQMAVFIHNFKRKGGIGGYSAGERI
-19 WRCGREGHQMKDCWE
-9 TVATLYCVHQRIDVK 55 . LVGKLNWASQIYPGIKVRQLCKLLR 84 . GYSAGERIVDIIATDIQTKELQKQI
-20 KDCWERQANFLGKIW
-10 CRIDVKDTKEALEKIE 56 . RQLCKLLRGTKALTEVIPLTEEAEL 85 . TKELQKQITKIQNFRVYYRDSRNPL
-21 CLGKIWPSYKGRPGNF
-11 CLEKIEEEQNKSKKKA 57 . PLTEEAELELAENREILKEPVHGVY 86 . YRDSRNPLWKGPSKLLWKGEGAVVI
-22 CRPGNFLQSRPEPTAPPE
-12 CSKKKAQQAAAAAGTG 58, KEPVHGVYYDPSKDLIAEIQKQGQG 87 . KGEGAVVIQDNSDIKVVPRRKAKII
-23 CEPTAPPEESFRFGEE
-13 CAAGTGNGSQVSQNY 59, EIQKQGQGQWTYQIYQEPFKNLKTG 88, PRRKAKIIRDYGKQMAGDDCVASRQ
-24 CRFGEEKTTPSQKQEPI
P24-1 PIVQNIQGQMVHQAIC 60 . PFKNLKTGKYARMRGAHTNDVKQLT 89 . DDCVASRQDED
-25 CPQKQEPIDKELYPLTS
-2 VHQAISPRTLNAWVKC 61, TNDVKQLTEAVQKITTESIVIWGKT 90 . LTQIGCTLNF
-26 CYPLTSLRSLFGNDPSSQ
-3 NAWVKVVEEKAFPEVC 62 . SIVIWGKTPKFKLPIQKETWETWWT 91 . PISPIETVPV
-4 AFPPEVIPMFSALSEC HIV -1 Peptides 63 . ETWETWWTEYWQATWIPEWEFVNTP 92 . LVSAGIRKIL
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-8 ETINEEAAEWDRVHPC 37, FIKVRQYDQILIEICGHKAIGTVLV 66 . NRETRLGKAGLYTNKGRQKVVPLTN K65 KGILGFVFKLTV
-9 DRVHPVHAGPIAPGQC 38 . KAIGTVLVGPTPVNIIGRNLLTQIG 67 . QKVVPLTNTTNQKTELQAIYLALQD FMP182-
-10 IAPGQMREPRGSDIAC 39 . RNLLTQIGCTLNFPISPIETVPVKL 68 . AIYLALQDSGLEVNIVTDSQYALGI 195 LASTTAKAMEQMAGS
-13 NPPIPVGEIYKRWIIC 40 . IETVPVKLKPGMDGPKVKQWPLTEE 69 . DSQYALGIIQAQPDQSESELVNQII
-14 KRWIILGLNKIVRMYC 41 . KQWPLTEEKIKALVEICTEMEKEGK 70 . SELVNQIIEQLIKKQKVYLAWVPAH
-16 LDIRQGPKEPFRDYVC 42 . TEMEKEGKISKIGPENPYNTPVFAI 71 . YLAWVPAHKGIGGNEQVDKLVSAGI
-17 FRDYVDRFYKTLRAEC 43 . YNTPVFAIKKKDSTKWRKLVDFREL 72 . DKLVSAGIRKILFLDGIDKAQDEME
-20 VQNANPDCKTILKALY 44 . KLVDFRELNKRTQDFWEVQLGIPHP 73 . DKAQDEHEKYHSNWRAMASDFNLPPResults
HLA Class IMoleculesBind to Peptide-coated Plates.
￿
To ex-
amine the binding ofpurifiedMHC class I molecules to pep-
tides, class I was iodinated and added to glutaraldehyde-treated
polyvinylchloride plates coated with synthetic peptides . Two
peptides derived from the influenza A matrix protein were
used in these studies : K65, an analogue of influenza matrix
protein (IMP) 57-68 with a lysine substitution for threo-
nine at position 65,which will block sensitization ofA2 target
cells with FMP57-68 (and therefore must bind to A2), and
IMP 182-195, which does not sensitize targets and there-
fore presumably does not bind (8, 9) . Both peptides are soluble
under out experimental conditions . Fig. 2 shows a titration
curve of iodinated HLA-A2 binding to plates . As easily seen,
the binding is fivefold greater than the binding to IMP 182-
195-coated wells . It is dependent on the amount of radiola-
beled A2 added . In this experiment the observed binding
represents 10% of the labeled protein added. The fraction
ofbound class I counts varied among experiments . In most
experiments between 10 and 25% of the added counts bound
to the plate .
Despite the purity of the class I preparations established
by SDS-PAGE and IEF, we still wished to exclude the possi-
bility that the observed binding was due to some con-
taminating protein . To exclude this, we modified the binding
assay to detect the binding of A2 to peptide-coated plates
using mAbs toMHC proteins. Both direct and indirect assays
have been used, which give essentially identical results. The
direct binding assay uses a directly iodinated mAb (e.g.,
MA2.1), the indirect assay uses iodinated or alkaline phos-
phatase-coupled goat anti-mouse antibody second antibody.
Shown in Fig . 3 is a titration of a preparation of unlabeled
HLA A2 binding to K65-coated plates, detected with 1251-
Figure 2 .
￿
Direct binding of 1251-labeled HLA-A2 to peptides. (/)
Wells coated with K65; (0) wells coated with FMP 182-195 .
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labeledMA2.1 Fab fragments. Similar results were seen using
the monomorphic class I-specific antibody W6/32 . A typ-
ical experiment usingW6/32 and goat anti-mouse antibody
coupled to alkaline phosphatase is shown in Fig. 4 . Here we
see no binding to peptide P24-4, but good binding to both
K65 and P24-2. These results demonstrate that the material
binding in the direct assay must contain intact class I pro-
tein, and not some contaminating material . This must be
so since both MA2.1 and W6/32 require 02 microglobulin
association for antibody binding.
BindingAssay Is Pl'ptide Specific
￿
To examine the specificity
ofbinding of class I proteins to peptide-coated plates,we tested
a series of 102 peptides from theHIV gag andHIVpol genes.
All were tested at least three times in the binding assay. The
gag peptides were tested both using the direct binding by
iodinatedA2 and detection of binding usingW6/32 and goat
anti-mouse antibody coupled to alkaline phosphatase. The
peptides that produced binding in the binding assay>10 SD
above the binding to the negative control (BSA coated wells)
are designated """, those >5 SD more than the negative con-
trols are indicated by "" ; those that bound >3 SD are indi-
cated by ` ; those that bound <3 SD are considered negative
and are designated -. Known cytotoxic T cell epitopes are
boxed. The binding of the gag peptides is shown in Table
1 . The pol peptides that bound HLAA2 were : 37, 39, 55,
62, 75, 77, 78, 85, 86, 87, and 88 . The remainder of the
pol peptides did not bind A2 . Thus, most of the peptides
(gag, pot, and influenza), 74 of 102 tested, do not bind HLA-
A2 . We confirm the pattern ofA2 binding to the three gag
peptides previously reported (13) . We conclude from these
experiments that most peptides do not have a structure that
is compatible with binding to these purified class I molecules .
12000
1 10 100 1000 10000
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Figure 3 .
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Detection of native HLA-A2 binding to wells coated
with K65 (/) or BSA alone ([I). A2 is detected by binding of 1251-
labeled MA2.1 Fab fragments.0 .16
0 .14
0 .12
A 405 0 .08
0 .06
0 .04
0 .02
0
250 125 62 .5 31 .25
ng Protein added
Figure 4.
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Binding of HLA-A2 binding using an indirect ELISA
assay. Wells were coated with K65 (/) ; P24-2 (* ) ; P24-4 (0) ; or
BSA alone ([I) . W6/32 and alkaline phosphatase-conjugated goat
anti-mouse IgG were used for detection .
Determination ofBinding Constants ofPurified Class I Protein
for Peptide . We'could inhibit the binding of HLA class I
molecules to the peptides bound on plates by preincubation
of the class I proteins with soluble peptides . This is a crucial
result since it demonstrates that the binding of class I pro-
teins is saturable. Peptides that do not bind in the solid-phase
assay are not able to inhibit the binding to peptides fixed on
plates . These results allow us to calculate the affinity of A2
for any given peptide in solution . By using the direct binding
assay, we can measure the amount ofbindable A2 in any prep-
aration since we know the specific activity of the A2 . By
using a competition in solution assay we can estimate the
concentration ofunbound A2 and knowing the specific ac-
tivity can calculate the total amount of A2, and therefore
solve at every point all the relevant information to perform
a Scatchard analysis of binding of class I to peptides. The
result of this analysis of binding ofHLA-A2 to K65 is shown
in Fig . 5 . A single line drawn through these points allows
the B, to be extrapolated to be -1.5 x 103 , and the Kd is
N6 x 10-4 . A similar experiment was performed with B27
which gave a similar binding constant when tested with the
FMP matrix analogue K65 . It is possible that more than a
single affinity can be inferred from this plot . If two lines are
drawn the high affinityKQ is increased only by a factor of
2-3 to ti5 x 103 .
The Binding Assay Is not Allele Specific
￿
It is interesting
to note from the data in Table 1 that there is little difference
in the pattern of binding among A2, B27, and the A1/B8
mixture . Of the 34 gag peptides where both A2 and B27
were tested, 32 are concordant . 11 bind both A2 and B27,
and 2 bind only A2 . The concordance between A2 and the
A1/B8 sample is similar, where 12 of 15 peptides are concor-
dant . It is interesting to note that the peptides that bind only
830
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continued
a single class I protein were relatively weak binders. How-
ever, two of these weakly binding peptides are functional CTL
epitopes recognized by CTL . Inspection ofthe raw data sug-
gests that even some of these peptides bound B27 above back-
ground as well, but the number of counts bound did not
reach statistical significance. Thus, even the small number
ofdiscrepancies that we see heremay over represent the number
of peptides that bind specifically to a single class I protein .
Antibodies to a1a2 Block Peptide Binding.
￿
To examine the
site ofbinding ofthe class I molecules, we usedmAbs W6/32
andMA2.1 to block the binding ofA2 to the plate. MA2.1
binds to residues in a1, while W6/32 binds elsewhere, and
would not be expected to alter binding (18) . As shown in
Fig . 6, addition of MA2.1 at the same time as A2 to the
plate, caused a50% inhibition ofbinding. In contrast, addi-
tion ofW6/32 had no effect . As a control, we testedMA2.1
on B27 binding to K65 . In this experiment, we saw no inhi-
bition ofB27 binding. Thus the inhibition is specific. These
experiments suggest that the binding of class I to peptide
is mediated by the ala2 peptide binding domain .
Table 1 .
to HIV gag
Direct Binding
peptides
of Purified HLA Class I Molecules
Peptide A2 Al/B8 B27
P24-1 - NT NT
P24-2 * * NT
P24-3 - NT -
P24-4 - NT NT
P24-5 - NT NT
P24-7 - NT -
P24-8 - NT NT
P24-10 - NT -
P24-13 - * NT
P24-14 NT
P24-16 - NT NT
P24-17 - NT NT
P24-20
P24-21 NT
P24-22 NT
P24-23 **
P17-1 - NT
P17-2 * -
[P17-3
P17-4 */- NT
P17-5 NT
P17-6 NT
P17-7 ***
P17-8 * * NTK65
Discussion
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Results of direct binding of 1251-labeled class I molecules to peptides.
All samples were tested in sextuplicate and the standard deviation of
the cpm bound determined. Binding is indicated relative to BSA-
blocked wells. (-) Binding < 3 SD greater than the BSA-blocked
wells; (*) binding 3-5 SD above the blocked wells; (**) binding
5-10 SD above the blocked wells; (***) binding >10 SD above the
blocked wells. (NT) Not tested. Peptides that are known to be
recognized by gag-specific CTL are boxed. Peptides P24-13, P24-20,
and P17-3 are recognized by B8-restricted CTL; peptide P24-14 is
recognized by B27-restricted CTL; peptide P17.8 is recognized by
A2-restricted CTL.
The evidence for MHC class II proteins binding to pep-
tides seems unequivocal. Both functional studies, which
showed that peptides added to fixed APCs could stimulate
T cell proliferation, and the direct binding experiments using
purified class II molecules have given largely consistent results
(3-6). Further, there has been a good correlation of the ability
of peptides that bind to a given allelic form of a class I mole-
cule to stimulate a T cell response restricted by that same
molecule (5). Thus, there is a strong correlation of the bio-
chemical binding data and the antigen presentation function
of the class II proteins tested. Further, the results of Roy et
al. have suggested that every peptide is likely to bind some
class II molecule (19). When they tested the peptides derived
from X repressor protein, almost all of the peptides could
stimulate a T cell proliferative response in one or another
mouse strain. The data suggest that all these peptides could
bind to at least one class II protein.
In contrast to the biochemical work on class II, the data
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Figure 5.
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Scatchard plot of
B the binding of HLAA2 to K65.
reported for class I by Chen and Parham (12), Bouillot et al.
(13), and Chen et al. (20) and those reported here are consis-
tent with each other and are different from the classII binding
data (5). We note that A2 and B27 bind largely, but not ex-
actly, the same peptides from the set derived from the HIV
gag sequence. The A2-restricted gag epitope P17-8 (Nixon,
D., and F. Gotch, personal communication), and the B27-
restricted epitope P24-14 (21) are both bound by both A2
and B27. This is consistent with the other results reported
here that peptides that bind either A2 or B27 usually bind
both proteins. The other known gag CTL epitopes (P24-13,
P24-20, and P17-3) (F. Gotch, personal communication), all
ofwhich are restrictedby B8, bind at leastone classI protein.
The apparent differences between class I binding and class
II binding are not as great as they might first appear. We
have examined only three human classI proteins, derived from
different loci, HLAA and -B. In contrast, much ofthe direct
binding studies performed in the mouse used class II pro-
teins and peptides that had already been shown to be under
Ir gene control. That means that rather than scanning a large
protein sequence as we have with gag and pol, they tested
a small series of peptides, which had already been shown to
be differently recognized by mice expressing different class
CPM Bound
250,000
200,000
150,000
100,000
50,000 -
0
MA2 .1 W6/32
50 500 5000
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￿
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Figure 6.
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MA2.1 but not W6/32 inhibits the binding of HLA-A2
to K65. Dilutions of each of the mAbs were added to the assay as
described in Materials and Methods.
Table 1 .
Peptide
(continued)
A2 Al/B8 B27
P17-9 * * NT
P17-10 - NT
P17-11 - -
P17-12 - -
P17-13 - NT
P15-14 * NT
P15-15 *** ** ***
P15-16 * ** **
P15-17 - NT -
P15-18
**
P15-19
P15-20
P15-21 ** NT NT
P15-22 - NT -
P15-23 ** NT **
P15-24 - - NT
P15-25 - NT
P15-26 - NT NTII proteins. Thus, a direct comparison of the data is not ap-
propriate. However, some of the peptides are not bound by
all class I molecules and so would be good candidates for
peptides under Ir-like gene control.
There is likely to be a fundamental difference between the
mechanism of peptide association with class I and class II.
It appears that for class II binding to peptides in vivo, much
of the association occurs after class II synthesis and expres-
sion via protein recirculation in the endosomes. In contrast,
it appears that peptide association with class I in vivo may
be a critical event in the initial assembly of class I molecules
for export to the cell surface, and relatively little recycling
occurs (22). The binding we describe must reflect the binding
of already assembled proteins to the appropriate peptides.
Judging from the relatively small number of peptides (com-
pared with all possible peptides) we have tested it appears
the correlation with known CTL epitopes is excellent.
Recent studies using competition for sensitization of target
cells with a known CTL peptide epitope have suggested that
while a large number of peptides bind to class I proteins,
the binding is allele specific (23). Our results here are in ap-
parent conflict with this conclusion. Although 25-42% of
a set ofpeptides tested were notedto inhibit CTL in an allele
specific manner, this result cannot be extrapolated to all class
I proteins since over 100 different class I proteins are known.
Further, another important difference is the peptides we tested
are an ordered set derived from a single protein sequence rather
than "random" peptides.
The binding ofpeptides that are not epitopes is expected.
The immune response in any individual is the result ofboth
the innate T cell repertoire and selection. We would be sur-
prised if all of the synthetic peptides that bound to class I
were actually recognized. A fraction might never be produced
from the antigenic protein in the cell by natural cellular pro-
cessing. Some would be unreactive because the appropriate
TCR was removed from the repertoireby tolerance, and others
because no appropriate TCR was encoded in the germline.
Given these constraints, together with the necessity to make
a CTL response to a wide array of viral proteins, it is advan-
tageous for class I proteins to bind peptides permissively.
It is possible that during purification and iodination that
some ofthe class I becomes denatured and the denatured pro-
teins are the ones that participate in the binding assayin vitro,
where, as they bind peptide, they renature. This would be
consistent with the large fraction ofclass I protein molecules
that are detected in the direct binding by iodinated class I
compared with the fraction ofmolecules detected in the class
II binding assays. These results are also in general consistent
with the results ofTownsend and colleagues on peptide sta-
bilized chain association (22).
The binding of class I is specific, as neither A2 nor B27
binds nonspecifically to the BSA blocking the plate, or to
numerous other peptides. Similarly, the labeled MA2.1 and
W6/32 did not bind nonspecifically to peptide or plates. We
know that the class I molecule is binding rather than some
other molecule present in the iodinated class I preparations.
Two linesofevidence support this contention. First, the prepa-
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rations are almost pure. When the iodinated peptide is im-
munoprecipitated, and run on isoelectric focusing gels, only
the A2 or B27 heavy chain bands are detected (along with
(32 microglobulin). Actin contamination was minimal, as
was contamination with other class I proteins. The second
line ofevidence is the detection of classI binding to the plates
using mAbs to class 1. mAbs directed at both monomorphic
and polymorphic epitopes on class I molecules couldbe used
to detect specific binding of class I proteins to the plates.
The binding constants we have measured are lower than
those reported for class II binding to peptide. This cannot
be the result of a solid-phase assay vs. a solution assay, since
we have measured the inhibition of binding by peptide to
HLA in solution, and only used the solid-phase assay to mea-
sure the binding of the unbound fraction ofthe class I. There
are two sources of error in the estimation of the binding con-
stants. First is the estimation of the total concentration of
class I introduced into the assay. This error is likely to be
less than a factor of two, since A2 was measured by an im-
munoassay. The other likely source oferror is the estimation
of the unbound class I fraction. This might be underesti-
mated because some of the molecules would be inactivated
during iodination, and hence contribute to the total number
of counts, but would ofnecessity remain unbound. We have
corrected for this error in the calculation, since we only de-
termine the binding constant using the totalnumber ofbind-
able counts, rather than the totaladded. Ifthere is significant
exchange of peptides by the class I protein at 4°C during
the solid-phase assay, we would have underestimated the bound
fraction and therefore underestimated the K,. Thus, while
there are sources of potential error in the measurement of
affinity of assembled class I for peptide they are unlikely to
alter the results by several orders of magnitude. The calcu-
lated affinities are N10-fold less than those reported for class
II. The ability of this assay to detect such low affinity binding
could result, at least in part, in the apparent differences we
see in the binding of class I and class II to peptides.
The central issue raised by the data presented here is the
promiscuous binding. The question we must address is
whether the binding measured has any relationship to the
binding detected by the CTL. Several points can be made
to encourage us that this binding is relevant. First, three of
five of the peptide epitopes that have been identified in HIV
gag bind A2, although only one A2-restricted epitope is known
to be present in this set of peptides. When the other two
peptides were tested with the B8 (their defined restriction
element) and A1 mixture, those peptides were shown to bind
as well. Thus, all of the identified peptide epitopes bind to
class I in the binding assay. Indeed, when we examined a
subset of the peptides reported here, for their ability to sensi-
tize A2 and B27 target cells, we noted that the two peptides
that consistently blocked, K65 and P15-5, also bound class
I (Wain, E., J.A. Frelinger, and A.J. McMichael, unpublished
data).
Thus, while the binding is permissive, it is not without
meaning. The biology of the immune response is consistent
with permissive binding. Nearly every virus can induce aspecific CTL response, in nearly all individuals who must
haveT cell repertoires selected by different MHCs . Thus the
variation in peptides recognized which correlates withMHC
type might not be the result of altered binding of peptides,
but rather the result of altered thymic selection . This is con-
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